✨ Free AI Report
Illumina, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Illumina, Inc.
Company Research

Illumina, Inc.: Business Overview, Financials & Competitive Analysis

Illumina, Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). Strong clinical consumables momentum and proteomics expansion offer growth catalysts, but research headwinds and China uncertainty create execution risks. Q4 2025 results exceeded expectations, with 20% growth in clinical consumables revenue ex-China. However, China remains an open question with the company bringing proteomics into the mix, and the key question.

What is Illumina, Inc.'s industry? Illumina, Inc. (illumina.com) operates in Life Sciences Tools & Genomic Sequencing. AskCyborg classifies Illumina, Inc. under Life Sciences Tools & Genomic Sequencing in its company registry.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications, generating over 90% of its revenue from sequencing instruments, consumables, and services. The company ...

6/ 10Solid

Cyborg Score thesis

Strong clinical consumables momentum and proteomics expansion offer growth catalysts, but research headwinds and China...

Read the full analyst-debate transcript →
Industry Life Sciences Tools & Genomic Sequencing
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Illumina, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Illumina, Inc.

AskCyborg analysts argue the bull and bear cases for Illumina, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Illumina, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Illumina, Inc. Overview

Pro stress-test →

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications, generating over 90% of its revenue from sequencing instruments, consumables, and services. The company is a dominant player in DNA sequencing and genomic analysis, serving research institutions, hospitals, and pharmaceutical companies globally.

Strategic Profile

Pro stress-test →

Management expects double-digit to mid-teens growth for the clinical business in 2026, while acknowledging ongoing challenges and muted growth in the research segment. In early February 2026, Illumina closed its SomaLogic acquisition, expanding into proteomics to build diversified multiomics capabilities.

Competitive Landscape

Pro stress-test →

Bio-Rad Laboratories, Bio-Techne, Pacific BioSciences of California, QuidelOrtho, and Idexx Laboratories are among Illumina's 41 competitors. Illumina maintains market leadership in high-throughput sequencing but faces competition from specialized players in lower-throughput applications and emerging proteomics platforms.

Industry Context

Illumina, Inc. operates in Life Sciences Tools & Genomic Sequencing.

Key facts

Founded: 1998 · Headquarters: San Diego, US · Employees: ~7,500 · Revenue: $4.34B · Market cap: $20.4B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Illumina, Inc..

  • 2026 revenue guidance of $4.5 billion-$4.6 billion exceeds consensus estimate of $4.4 billion
  • Ex-China organic growth expected between 2% and 4% with non-GAAP operating margin of 23.3% to 23.5%
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Closed $425 million SomaLogic acquisition to expand into proteomics
  • February 2026Issued 2026 guidance for $4.5-4.6B revenue with clinical business expected to grow double-digit to mid-teens
  • +1 moreTrack every material event for Illumina, Inc. as it happens. Explore monitoring →
Get alerted when Illumina, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

PacBioLong-read sequencing technology→Bio-RadLife science research tools and diagnostics→Bio-TechneBiotech and life science reagents→Thermo Fisher ScientificDiversified life sciences company→

Compare Illumina, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Illumina, Inc. operates in Life Sciences Tools & Genomic Sequencing. See how the rest of the sector scores on the Cyborg framework.

Browse Life Sciences Tools & Genomic Sequencing research →
NEW · MCP server

Ask your AI assistant about Illumina, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Illumina, Inc. and its top competitor on Cyborg Score”
“What did Illumina, Inc. do this quarter?”
“Is Illumina, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Illumina, Inc. do?+
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications, generating over 90% of its revenue from sequencing instruments, consumables, and services. The company ...
What is Illumina, Inc.'s Cyborg Score?+
Illumina, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Illumina, Inc.'s main competitors?+
Named competitors include PacBio, Bio-Rad, Bio-Techne, Thermo Fisher Scientific. The full competitive landscape is in the AskCyborg report.
How can I get the full Illumina, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Illumina, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Illumina, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.